NeuroScientific Biopharmaceuticals (ASX:NSB) - Managing Director & CEO, Matthew Liddelow
Managing Director & CEO, Matthew Liddelow
Source: TechInvest Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Drug development company, Neuroscientific Biopharmaceuticals (NSB) has signed a manufacturing agreement with leading Japanese company, Mitsubishi Corporation
  • Under the agreement, Mitsubishi’s invested company PeptiStar will undertake feasibility and analytical services for large-scale manufacturing of the EmtinB drug for future clinical programs
  • EmtinB is currently being developed as a treatment for Alzheimer’s disease
  • NSB remains steady on the market today, trading for 18¢ per share

Drug development company, Neuroscientific Biopharmaceuticals (NSB) has signed a manufacturing agreement with leading Japanese company, Mitsubishi Corporation.

Under the agreement, Mitsubishi’s invested company PeptiStar will undertake feasibility and analytical services for large-scale manufacturing of the EmtinB drug for future clinical programs.

NSB expects this to begin in the second half of 2020.

EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease.

CEO and Managing Director Matt Liddelow is pleased with the agreement.

“NSB is excited to be working with PeptiStar and its globally recognized parent company, Mitsubishi,” he said.

“These companies will add significant peptide manufacturing expertise to NSB’s clinical development programs and we hope this agreement will be the first step towards a long-term manufacturing partnership with Mitsubishi and PeptiStar,” he added.

Recently, NSB announced significant positive results in a novel treatment for Multiple Sclerosis.

NSB remains steady on the market today, trading for 18¢ per share at 1:37 pm AEST.

NSB by the numbers
More From The Market Herald
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.